Skip to main content

Table 2 Therapeutic efficacy in patients stratified by AFP level

From: Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis

Characteristic

AFP level(ug/L) < 400, N = 42

AFP level(ug/L) ≥ 400, N = 38

D-P-T/H, N = 261

S-P-T/H, N = 161

p-value2

D-P-T/H, N = 241

S-P-T/H, N = 141

p-value2

mRECIST

  

0.482

  

0.052

 CR

3 (12%)

0 (0%)

 

1 (4%)

0 (0%)

 

 PR

15 (58%)

9 (56%)

 

13 (54%)

3(21%)

 

 SD

7 (27%)

5 (31%)

 

9 (38%)

7 (50%)

 

 PD

1 (3%)

2 (13%)

 

1 (4%)

4 (29%)

 

 ORR

18 (69%)

9 (56%)

0.394

14 (58%)

3 (21%)

0.027

 DCR

25 (96%)

14 (88%)

0.547

23 (96%)

10 (71%)

0.052

  1. 1n (%)
  2. 2 Fisher’s exact test; Pearson’s Chi-squared test
  3. ORR: Objective response rate; DCR: Disease control rate; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us